Program
ponesimod
Also written as “Ponesimod”, “ACT-128800” and “Ponesimod 10 mg”.
Its studies are mostly in Multiple Sclerosis · Psoriasis · Colitis, Ulcerative · Bronchiolitis Obliterans Syndrome, led by 2 companies.
Drug pagePonesimod: every studyAll 16 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 140 open or running | phase 3since Apr 21, 2015 | Feb 26, 2009 | none ahead |
| Vanda Pharmaceuticals | 22 open or running | phase 3since Jan 20, 2026 | Jan 20, 2026 | Aug 2028phase 3 · NCT07362017 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Vanda Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 20, 2026First study: phase 3 study in PsoriasisFirst studyNCT07362017 · 300 planned · United States
- Jun 30, 2026Phase 3 study in Colitis, UlcerativeNCT07686081 · 150 planned · United States
Ahead
- Aug 2028Primary completion: phase 3 study in PsoriasisNCT07362017
- Apr 2029Primary completion: phase 3 study in Colitis, UlcerativeNCT07686081
TargetBeta
“An orally available sphingosine-1-phosphate receptor 1 (S1PR1, S1P1) agonist that acts as a functional antagonist, ”NCIt, by rule
“Sphingosine 1-phosphate receptor Edg-1 agonist”ChEMBL 37, by rule
Other programs on S1PR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| fingolimodrule | Novartis | phase 4 | 55 |
| etrasimodrule | Pfizer | phase 3 | 21 |
| cenerimodrule | Viatris | phase 3 | 14 |
| mocravimodrule | Novartis | phase 3 | 5 |
Studies
All 2 Vanda Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07686081Colitis, Ulcerative · United States | 3 | Recruiting | Apr 2029 | 150 |
| NCT07362017Psoriasis · United States | 3 | Recruiting | Aug 2028 | 300 |
How it is read
Names in the registry
- “Ponesimod”, 6 entries
- “ACT-128800”, 5 entries
- “Ponesimod 10 mg”, 2 entries
- “Ponesimod 20 mg”, 2 entries
- “Ponesimod 40 mg”, 2 entries
Conditions, from the studies’ own filings
- Multiple Sclerosis, 5 studies
- Psoriasis, 3 studies
- Colitis, Ulcerative, 1 study
- Bronchiolitis Obliterans Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.